Table 1.
State-of-the-art in the approach to treatment of STIs in Europe.a
Antibiotics with intrinsic proven activity in wild-type strains | Widespread antimicrobial resistant strains | Current first-line | Second line when allergy or treatment failure | Third line after treatment failure or resistance | Resistance guided therapy | Pregnancy | Empirical combination | |
---|---|---|---|---|---|---|---|---|
Gonorrhoea | Penicillin, cephalosporins, carbapenems, tetracyclines, macrolides, aminoglycosides, and fluoroquinolones | Penicillin, fluoroquinolones, tetracyclines, macrolides |
|
|
Guided by resistance testing |
Quinolone susceptibility confirmed by molecular tests:
|
|
|
Mycoplasma genitalium | Tetracyclines, macrolides, fluoroquinolones, and streptogramins | Macrolides, fluoroquinolones |
|
|
|
Initial syndromic treatment:
|
|
|
Syphilis | Penicillin, cephalosporins, macrolides, tetracyclines, oxazolidinones | Azithromycin |
Primary, secondary, and early latent syphilis:
|
Primary, secondary, and early latent syphilis with penicillin allergy:
|
First line is BPG, in case of penicillin allergy:
|
Treatment Guidelines (Europe): https://iusti.org/treatment-guidelines/-accessed 10 June 2023.
Similar Guidelines are available online: https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf (USA); https://sti.guidelines.org.au/ (Australia); https://www.bashh.org/guidelines (UK). BPG: Benzathine penicillin G.